(:NVTA)
Business Focus: N/A
Apr 11, 2024 11:30 am ET
Invitae Unveils New Research for Breast Cancer Patients with Variants of Uncertain Significance
– Study findings to be presented at the 2024 American Society of Breast Surgeons Annual Meeting –
Feb 13, 2024 09:07 pm ET
Invitae Files for Voluntary Chapter 11 Protection; Pursues Sale Process
– Company to Use its Cash on Hand to Operate its Business During the Proceedings and Continues to Serve Customers and Patients –
Jan 30, 2024 06:00 am ET
Invitae Partners with BridgeBio Pharma to Harness Genetic Insights for the Discovery of Rare Disease Therapeutics
SAN FRANCISCO, Jan. 30, 2024 /PRNewswire/ -- Invitae (NYSE: NVTA), a leading medical genetics company, today announced a partnership with BridgeBio Pharma, Inc. (Nasdaq: BBIO), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, designed to advance genetics-based drug discovery for rare diseases. The goal of the collaboration is to generate new insights focused on genetic modifiers and the discovery of novel therapeutic targets for rare diseases and other unmet medical needs.
Jan 22, 2024 06:00 am ET
Invitae Completes Sale of Reproductive Health Assets to Natera
SAN FRANCISCO, Jan. 22, 2024 /PRNewswire/ -- Invitae (NYSE: NVTA), a leading medical genetics company, today announced it has completed the sale of certain reproductive health assets, which include carrier screening and non-invasive prenatal screening, to Natera (NASDAQ: NTRA).
Dec 13, 2023 03:05 pm ET
Invitae Divests Ciitizen Health Data Platform and Implements Further Cost Cuts
– Maintains Minority Equity Stake in Ciitizen –
Nov 08, 2023 03:01 pm ET
Invitae Reports Third Quarter 2023 Financial Results
Reported revenue of $121.2 million, a year-over-year decrease of 9%; on a pro forma basis, taking into account exited businesses and geographies, revenue increased approximately 4%
Nov 06, 2023 03:00 pm ET
Invitae Launches Enhanced Chemistry of MRD Test to Better Serve Biopharmaceutical Clinical and Research Partnerships
– Helps to detect circulating tumor DNA (ctDNA) as a biomarker in clinical research and clinical trials for solid tumor malignancies –
Nov 01, 2023 06:59 am ET
Invitae to Announce Third Quarter 2023 Financial Results on Wednesday, November 8, 2023
SAN FRANCISCO, Nov. 1, 2023 /PRNewswire/ -- Invitae (NYSE: NVTA), a leading medical genetics company, today announced that it will report its third quarter 2023 financial results on Wednesday, November 8, 2023, and will host a conference call and webcast that day at 4:30 p.m. Eastern / 1:30 p.m. Pacific to discuss its financial results and recent highlights.
Oct 25, 2023 11:00 am ET
Landmark Study Reveals Magnitude of Uncertain Results in Clinical Genetic Testing for Hereditary Disease, Points to Evidence-Based Solutions to Reach Definitive Results
– Findings set to enhance patient care and reduce uncertainty in test results as clinicians advance precision healthcare for hereditary disease –
Oct 19, 2023 04:30 pm ET
Invitae Appoints Dr. David Sholehvar as Chief Operating Officer
SAN FRANCISCO, Oct. 19, 2023 /PRNewswire/ -- Invitae (NYSE: NVTA), a leading medical genetics company, today announced the appointment of veteran healthcare leader David Sholehvar, M.D., as chief operating officer, effective November 13, 2023. Dr. Sholehvar is a healthcare business leader with a 25-year track record of successfully solving complex problems and leading business transformations, addressing regulatory challenges and developing new product and growth strategies.
Oct 12, 2023 04:15 pm ET
Rural Hospital System Demonstrates the Clinical Benefits of Implementing Universal Hereditary Cancer Testing in Patients with Breast Cancer
– Invitae retrospective analysis reinforces the clinical actionability of following the ASBrS guidelines –
Oct 10, 2023 04:30 pm ET
Invitae to Present Data at the National Society of Genetic Counselors 42nd Annual Conference That Supports Advancements in Medical Genomics
- Sponsor of the Heart of Genetic Counseling program and award, recognizing excellence in patient care -
Oct 03, 2023 12:07 pm ET
Invitae's Common Hereditary Cancers Panel Receives FDA Market Authorization
– First-of-its-kind authorization provides potential marketing differentiation and opportunities for largest testing category –
Sep 25, 2023 04:30 pm ET
Invitae Announces Appointment of Finance Veteran Ana Schrank as CFO
SAN FRANCISCO, Sept. 25, 2023 /PRNewswire/ -- Invitae (NYSE: NVTA), a leading medical genetics company, today announced the appointment of finance veteran Ana Schrank as the Company's chief financial officer (CFO), effective October 2. Robert Dickey, who has been the Company's interim CFO since August 2023, will transition to a consulting role for the Company and will work closely with Ms. Schrank and the leadership team to ensure a smooth transition.
Sep 22, 2023 04:30 pm ET
Invitae Receives Notice of Non-Compliance with NYSE Minimum Share Price Continued Listing Standard
SAN FRANCISCO, Sept. 22, 2023 /PRNewswire/ -- Invitae (NYSE: NVTA), a leading medical genetics company, today announced that it received a notice from the New York Stock Exchange (the "NYSE") on September 20, 2023, indicating the company is not currently in compliance with Section 802.01C of the NYSE Listed Company Manual because the average closing price of the company's common stock over a consecutive 30 trading-day period was less than $1.00 per share. The NYSE notice has no immediate effect on the listing of the common stock on the NYSE, subject to the company's compliance with the NYSE'
Jul 26, 2023 04:01 pm ET
Invitae to Announce Second Quarter 2023 Financial Results on Tuesday, August 8, 2023
SAN FRANCISCO, July 26, 2023 /PRNewswire/ -- Invitae (NYSE: NVTA), a leading medical genetics company, today announced that it will report its second quarter 2023 financial results on Tuesday, August 8, 2023, and will host a conference call and webcast that day at 4:30 p.m. Eastern / 1:30 p.m. Pacific to discuss its financial results and recent highlights.
May 31, 2023 06:59 am ET
Invitae to Present at the William Blair 43rd Annual Growth Stock Conference
SAN FRANCISCO, May 31, 2023 /PRNewswire/ -- Invitae (NYSE: NVTA), a leading medical genetics company, today announced that Ken Knight, president and chief executive officer, will present at the William Blair 43rd Annual Growth Stock Conference on Wednesday, June 7, 2023, at 12:40 p.m. Central Time.
May 26, 2023 08:01 am ET
New Research Insights to be Presented by Invitae at the 2023 ASCO Annual Meeting Reinforce the Critical Role of Germline Genetic Testing in Oncology
– Study findings confirm the importance of improving education among clinicians and streamlining processes to increase adoption of testing in routine cancer care –
May 25, 2023 07:00 pm ET
Invitae Announces CFO Transition and Selection of Veteran Finance Executive Christine Gorjanc as Interim CFO
SAN FRANCISCO, May 25, 2023 /PRNewswire/ -- Invitae (NYSE: NVTA), a leading medical genetics company, today announced that Chief Financial Officer (CFO) Yafei (Roxi) Wen is resigning to pursue other opportunities, effective June 30, 2023. The Company has initiated a search for a new CFO. Ms. Wen will continue in her role through the end of the second quarter. Christine Gorjanc, the Company's longtime Chair of the Audit Committee of the Board of Directors, will assist during the transition and will assume the role of interim CFO, effective July 1, 2023. Ms. Wen will work closely with Ms. Gorj
May 15, 2023 04:07 pm ET
Invitae to Appeal Trial Verdict
SAN FRANCISCO, May 15, 2023 /PRNewswire/ -- Invitae (NYSE: NVTA), a leading medical genetics company, today announced that it intends to appeal the verdict delivered by a jury at the United States District Court for the District of Delaware. The jury found that Invitae's products using Anchored Multiplex PCR ("AMP") chemistry infringe certain Natera, Inc. patents. The jury awarded Natera a total of $19.35 million, based on lost profits and a royalty rate of 10% on certain products. Invitae will vigorously defend itself in future proceedings regarding Natera's request for injunctive relief.
May 09, 2023 04:01 pm ET
Invitae Reports First Quarter 2023 Financial Results
– Reported revenue of $117.4 million, a 5% year-over-year decrease due to exited businesses and geographies; pro forma year-over-year revenue growth was ~10% –
Apr 26, 2023 06:59 am ET
Invitae to Announce First Quarter 2023 Financial Results on Tuesday, May 9, 2023
SAN FRANCISCO, April 26, 2023 /PRNewswire/ -- Invitae (NYSE: NVTA), a leading medical genetics company, today announced that it will report its first quarter 2023 financial results on Tuesday, May 9, 2023, and will host a conference call and webcast that day at 4:30 p.m. Eastern / 1:30 p.m. Pacific to discuss its financial results and recent highlights.
Apr 17, 2023 04:30 pm ET
Invitae Publishes Annual Environmental, Social and Governance (ESG) Report
– Report details the company's commitment to improve healthcare for all through its ESG and sustainability initiatives –
Apr 13, 2023 08:45 am ET
New Study Findings Published in Nature Show Circulating Tumor DNA (ctDNA) Can Predict and Detect Cancer Recurrence Earlier In Non-Small Cell Lung Cancer
– Highlights the use of Invitae's personalized cancer monitoring (PCM) technology to correlate clinical outcomes with minimal residual disease (MRD) presence –
Mar 22, 2023 07:30 am ET
Invitae and Deerfield Management Partner to Create Novel Therapeutics for Rare Diseases
– The partnership will harness genetic and clinical data from millions of patients tested at Invitae and Deerfield's expertise in drug discovery to address high unmet needs among rare disease patients –
Mar 21, 2023 07:30 am ET
Invitae Announces Partnership with Epic to Streamline Genetic Testing
– Collaboration will simplify providers' and patients' access to discrete test results that can inform more precise, personalized medicine –
Mar 16, 2023 07:30 am ET
Invitae Appoints Dr. W. Michael Korn as Chief Medical Officer for Oncology
– Expert in the field of gastrointestinal cancer and precision oncology to lead Invitae's medical oncology team with a particular focus on somatic testing development –
Mar 15, 2023 05:30 pm ET
Invitae to Present Data at The American Clinical Genetics Meeting 2023 That Supports Removing Barriers to Genetic Testing
– New research looking at underrepresented racial, ethnic and ancestry groups underscores the importance of universal germline genetic testing –
Feb 14, 2023 06:00 am ET
Invitae to Announce Fourth Quarter and Full Year 2022 Financial Results on Tuesday, February 28, 2023
SAN FRANCISCO, Feb. 14, 2023 /PRNewswire/ -- Invitae (NYSE: NVTA), a leading medical genetics company, today announced that it will report its fourth quarter and full year 2022 financial results on Tuesday, February 28, 2023, and will host a conference call and webcast that day at 4:30 p.m. Eastern / 1:30 p.m. Pacific to discuss its financial results and recent highlights.
Jan 30, 2023 06:30 am ET
Invitae Appoints William H. Osborne to its Board of Directors
– Brings invaluable expertise in leading, operating and scaling global businesses throughout his career in aerospace, transportation and integrated solutions –
Jan 09, 2023 06:00 am ET
Invitae Reports Preliminary 2022 Financial Results
— Approximately 12% growth year-over-year in revenues —— Greater than $555 million in cash, cash equivalents, marketable securities, and restricted cash —— Cash burn continued its declining trend over the past five quarters —— Presenting at the 41st Annual J.P. Morgan Healthcare Conference on January 11 at 9:00 a.m. PST —
Jan 04, 2023 06:30 am ET
Invitae to Present at the 41st Annual J.P. Morgan Healthcare Conference
SAN FRANCISCO, Jan. 4, 2023 /PRNewswire/ -- Invitae (NYSE: NVTA), a leading medical genetics company, today announced that Ken Knight, president & chief executive officer, will present at the 41st Annual J.P. Morgan Healthcare Conference on Wednesday, January 11, 2023, at 12:00 p.m. Eastern / 9:00 a.m. Pacific.
Dec 20, 2022 06:30 am ET
Invitae Completes Selected Assets Sale of its Next Generation Sequencing (NGS) research assays to Integrated DNA Technologies, Inc.
— Invitae will continue to invest in its precision oncology focused lab developed test (LDT) offerings — — The transaction contributes to Invitae's cash runway and includes a strategic supply partnership to support the growth of Invitae Personalized Cancer Monitoring™ (PCM) services —
Dec 19, 2022 04:15 pm ET
Invitae Executive Appointed to National Health Information Technology Advisory Committee
– Deven McGraw to serve a 3-year term beginning in 2023 –
Dec 07, 2022 06:30 am ET
Invitae Releases Data Use Transparency Report, Demonstrating the Impact of Patient Data on Genetic Research
– Invitae to report on secondary patient data use, demonstrating real-world impact of de-identified patient data on the advancement of precision medicine –
Dec 01, 2022 06:30 am ET
Invitae Launches Rare Patient Network for Pediatric Patients With Rare Neurodevelopmental Diseases
– Ciitizen real-world data platform expansion helps advance research and potentially improve outcomes for patients with pediatric epilepsy and/or developmental delay –
Nov 10, 2022 09:13 am ET
Invitae Showcases Advances in Medical Genomics at the National Society of Genetic Counselors (NSGC) 41st Annual Conference
- Heart of Genetic Counseling Award recognizing excellence in patient care will be presented by Invitae and NSGC -
Nov 08, 2022 03:05 pm ET
Invitae Reports Third Quarter 2022 Financial Results
— Continued to execute against realignment plan and portfolio optimization initiatives —— Reported revenue of $133.5 million, a 16.7% YoY increase —— Cash, cash equivalents, restricted cash and marketable securities of $596 million as of 9/30 —— On track to achieve planned cash burn reduction of approximately $326 million, to be fully realized by 2023 —— 2022 cash burn guidance lowered; maintained other financial targets —— Conference call and webcast today at 4:30 p.m. Eastern Time / 1:30 p.m. Pacific Time —
Oct 31, 2022 05:13 pm ET
Invitae study shows therapy informed by genetic testing reduces seizures in some patients with epilepsy
– Results support universal genetic testing in all diagnosed patients with epilepsy to potentially improve health outcomes –
Oct 28, 2022 11:16 am ET
Invitae to Present Data at the American Society of Human Genetics Annual Meeting Furthering the Understanding of Variants of Uncertain Significance in Underrepresented Populations
– Presentations provide additional insights into the critical importance of advancing equity in genomics –
Oct 27, 2022 07:30 am ET
Invitae Announces Partnership for Real-World Data Sharing to Inform Rare Cancer Research
– Using Invitae's Ciitizen patient-driven data platform, AstraZeneca and the Cholangiocarcinoma Foundation will access lived experience of patients with a rare cancer to drive further research –
Oct 25, 2022 04:05 pm ET
Invitae to Announce Third Quarter 2022 Financial Results on Tuesday, November 8, 2022
SAN FRANCISCO, Oct. 25, 2022 /PRNewswire/ -- Invitae (NYSE: NVTA), a leading medical genetics company, today announced that it will report its third quarter 2022 financial results on Tuesday, November 8, 2022, and will host a conference call and webcast that day at 4:30 p.m. Eastern / 1:30 p.m. Pacific to discuss its financial results and recent highlights.
Sep 27, 2022 07:30 am ET
Invitae Appointed to National Quality Forum Committee on Quality Standards for Healthcare
– First genetics testing company to sit on Forum –
Sep 22, 2022 11:00 am ET
Clinical Practice Guidelines Recommend Genetic Testing of All Patients with Breast Cancer
– Invitae study reports universal genetic testing improves outcomes for patients with breast cancer –
Sep 20, 2022 08:30 am ET
Invitae’s Real-World Ciitizen Data Utilized in Praxis Precision Medicines’ PRAX-222 IND Filing
Invitae (NYSE: NVTA) and Praxis Precision Medicines, Inc. (NASDAQ: PRAX), today announced that real-world clinical insights from Invitae’s Ciitizen platform were utilized as natural history data to support the submission of Praxis’ Investigational...
Sep 20, 2022 07:30 am ET
Invitae's Real-World Ciitizen Data Utilized in Praxis Precision Medicines' PRAX-222 IND Filing
– First use of Ciitizen platform as source of real-world data in regulatory filing –
Sep 15, 2022 04:00 pm ET
Leading Clinical Experts Across the U.S. Unite to Support Universal Genetic Testing for all Patients with Cancer
– Clinicians agree that evidence supports testing benefits for all –
Sep 12, 2022 07:30 am ET
Invitae and Simons Searchlight Partner to Accelerate Research through Data Sharing
– Researchers will now be able to access rich clinical data on patients with rare neurological disease –
Aug 30, 2022 04:05 pm ET
Invitae to Present at Upcoming Investor Conference
SAN FRANCISCO, Aug. 30, 2022 /PRNewswire/ -- Invitae (NYSE: NVTA), a leading medical genetics company, today announced that members of its management team will participate in the following investor conference:
Aug 15, 2022 10:55 am ET
Thinking about buying stock in Team, Invitae, FuelCell Energy, Embark Technology, or Rivian Automotive?
NEW YORK, Aug. 15, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for TISI, NVTA, FCEL, EMBK, and RIVN.
Aug 12, 2022 11:36 am ET
Thinking about buying stock in Invitae, AMC Entertainment, Veru, Sailpoint Technologies, or Bed Bath & Beyond?
NEW YORK, Aug. 12, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for NVTA, AMC, VERU, SAIL, and BBBY.
Aug 11, 2022 11:25 am ET
Thinking about buying stock in Invitae, Timber Pharmaceuticals, Matterport, Nio, or Bed Bath & Beyond?
NEW YORK, Aug. 11, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for NVTA, TMBR, MTTR, NIO, and BBBY.
Aug 09, 2022 04:05 pm ET
Invitae Reports $136.6 Million in Revenue in Second Quarter of 2022
— Continued to execute towards operational excellence with portfolio optimization, broad cost controls and cash management —
Aug 08, 2022 11:45 am ET
New NCCN Colorectal Cancer Guidelines Recommend Genetic Testing for All Diagnosed Patients
- Significant changes made to current NCCN testing recommendations increase access to testing for historically underserved populations -
Aug 02, 2022 07:00 am ET
Invitae to Announce Second Quarter 2022 Financial Results on Tuesday, August 9, 2022
SAN FRANCISCO, Aug. 2, 2022 /PRNewswire/ -- Invitae (NYSE: NVTA), a leading medical genetics company, today announced that it will report its second quarter 2022 financial results on Tuesday, August 9, 2022, and will host a conference call and webcast that day at 4:30 p.m. Eastern / 1:30 p.m. Pacific to discuss its financial results and recent highlights.
Jul 18, 2022 04:13 pm ET
Invitae Announces Strategic Business Realignment to Accelerate Its Path to Positive Cash Flow and Realize Full Potential of Industry-Leading Genetics Testing Platform
— Exiting non-core businesses and geographies to prioritize higher-margin business initiatives —
Jul 18, 2022 04:05 pm ET
Invitae Announces Leadership Transition
— COO Kenneth D. Knight named CEO succeeding Sean George; Dr. George to continue as member of Board of Directors —
May 27, 2022 07:00 am ET
Invitae to Present at Upcoming Investor Conferences
SAN FRANCISCO, May 27, 2022 /PRNewswire/ -- Invitae (NYSE: NVTA), a leading medical genetics company, today announced that members of its management team will participate in the following investor conferences:
May 26, 2022 05:05 pm ET
New Research Demonstrates Genetic Information Can Transform Cancer Care, Guidelines Remain a Barrier to Patient Access
- New data to be presented by Invitae at 2022 ASCO Annual Meeting show importance of genetic testing for all cancer patients -
May 19, 2022 06:30 am ET
Invitae Launches Expanded Pharmacogenomics Panel and Specialized Mental Health Panel
- New 38-gene testing panel and clinical decision support tool analyzes a patient's genetics and co-medications for their impact on drug and dose personalization -
May 03, 2022 04:05 pm ET
Invitae Reports $123.7 Million in Revenue in First Quarter of 2022 and Extends Cash Runway
— Executing toward 2022 plan, generating near 20% revenue growth, with $885 million in ending cash*, an annualized burn reduction of greater than $100 million —
May 03, 2022 06:00 am ET
Allelica Collaborates with Invitae to Build Ancestry-Informed Polygenic Risk Score for Breast Cancer
Allelica and Invitae aim to decrease the gap in polygenic risk score (PRS) performance in individuals from diverse genetic ancestries, ensuring that the life-saving integration of genomic information into breast cancer risk assessments can benefit all women
Apr 20, 2022 06:59 am ET
Invitae to Announce First Quarter 2022 Financial Results on Tuesday, May 3, 2022
SAN FRANCISCO, April 20, 2022 /PRNewswire/ -- Invitae Corporation (NYSE: NVTA), a leading medical genetics company, today announced that it will report its first quarter 2022 financial results on Tuesday, May 3, 2022, and will host a conference call and webcast that day at 4:30 p.m. Eastern / 1:30 p.m. Pacific to discuss its financial results and recent highlights.
Apr 04, 2022 06:30 am ET
Invitae Introduces First Comprehensive Genetic Test Suite for Neurodevelopmental Disorders
– First to offer suite of tests in easy to access format for children with developmental disabilities –
Mar 29, 2022 06:30 am ET
Introducing Invitae Digital Health--A Personalized Health Management Platform That Leverages Genomic Insights to Inform Health Decisions for Patients and Clinicians
– Invitae launches seamless digital platform to enhance patient and provider experiences and further bring genetics to mainstream medicine –
Mar 17, 2022 06:30 am ET
Invitae Launches Full Access to its Liquid-Based Personalized Cancer Monitoring Platform to Help Detect Disease Earlier
– Personalized tumor-informed assay helps patients get ahead of cancer –
Mar 15, 2022 04:30 pm ET
Invitae Publishes the 2022 Environmental, Social and Governance Report
– Report details the company's dedication to healthcare for humanity through sustainable practices coupled with progress towards its mission –
Feb 24, 2022 03:05 pm ET
Invitae Reports $460.4 Million in Annual Revenue Driven by 1.17 Million in Billable Volume in 2021
SAN FRANCISCO, Feb. 24, 2022 /PRNewswire/ -- Invitae (NYSE: NVTA), a leading medical genetics company, today announced financial and operating results for the fourth quarter and year ended December 31, 2021.
Feb 16, 2022 02:00 am ET
Invitae Launches its First CE-IVD Cancer Testing Kits In Europe
SAN FRANCISCO, Feb. 16, 2022 /PRNewswire/ -- Invitae (NYSE: NVTA), a leading medical genetics company, today announced the availability of FusionPlex Dx® and LiquidPlex Dx™ in Europe, part of its industry-leading Anchored Multiplex PCR chemistry in-vitro diagnostic (IVD) products. Invitae is delivering essential high quality innovation for precision oncology in the fight against cancer.
Feb 10, 2022 05:59 am ET
Invitae to Announce Fourth Quarter and Full Year 2021 Financial Results on Thursday, February 24, 2022
SAN FRANCISCO, Feb. 10, 2022 /PRNewswire/ -- Invitae Corporation (NYSE: NVTA), a leading medical genetics company, today announced that it will report its fourth quarter and full year 2021 financial results on Thursday, February 24, 2022, and will host a conference call and webcast that day at 4:30 p.m. Eastern / 1:30 p.m. Pacific to discuss its financial results and recent highlights.
Feb 03, 2022 03:01 pm ET
Invitae to Present at Upcoming Investor Conferences
SAN FRANCISCO, Feb. 3, 2022 /PRNewswire/ -- Invitae Corporation (NYSE: NVTA), a leading medical genetics company, today announced that members of its management team will participate in virtual fireside chats at the following investor conferences:
Feb 03, 2022 01:37 pm ET
Invitae Supports the Biden Administration's Advancement of the Cancer Moonshot, Enhanced Recommendations on Genetic Testing for Cancer Treatment
SAN FRANCISCO, Feb. 3, 2022 /PRNewswire/ -- Invitae Corporation (NYSE: NVTA), a leading medical genetics company, applauds the Biden Administration's announcement to reignite the Cancer Moonshot with renewed White House leadership of this effort. As part of this initiative, the newly formed President's Cancer Panel also released a report on Closing the Gaps in Cancer Screening, which includes several important advancements in the use of genetic testing and access to genetic counselors for cancer patients.
Jan 10, 2022 05:59 am ET
Invitae Reports Preliminary 2021 Revenue of More Than $458 Million and Billable Volume of More Than 1.16 Million
SAN FRANCISCO, Jan. 10, 2022 /PRNewswire/ -- Invitae Corporation (NYSE: NVTA), a leading medical genetics company, announced preliminary unaudited full-year 2021 revenue, billable volume and commercial metrics reporting approximately 64 percent growth in revenue and 76 percent growth in volume, signaling continued momentum into 2022.
Jan 05, 2022 06:30 am ET
Invitae to Present Virtually at the 40th Annual J.P. Morgan Healthcare Conference
SAN FRANCISCO, Jan. 5, 2022 /PRNewswire/ -- Invitae Corporation (NYSE: NVTA), a leading medical genetics company, today announced that Sean George, chief executive officer, will present virtually at the 40th Annual J.P. Morgan Healthcare Conference on Wednesday, January 12, 2022, at 9:45 a.m. Eastern Time.
Nov 08, 2021 03:05 pm ET
Invitae Reports $114.4 Million in Revenue Driven by 296,000 in Billable Volume in Third Quarter of 2021
SAN FRANCISCO, Nov. 8, 2021 /PRNewswire/ -- Invitae (NYSE: NVTA), a leading medical genetics company, today announced financial and operating results for the third quarter ended September 30, 2021.
Nov 08, 2021 07:00 am ET
Northwestern University and Invitae Present New Research Highlighting the Importance of Genetic Testing for Cardiovascular Conditions at the American Heart Association Scientific Sessions
SAN FRANCISCO, Nov. 8, 2021 /PRNewswire/ -- Investigators from Northwestern University Feinberg School of Medicine and Invitae (NYSE: NVTA), a medical genetics company, will present the results of a collaborative study on genetic testing for heritable cardiomyopathies and arrhythmias at the American Heart Association (AHA) Scientific Sessions on Saturday, Nov. 13. The study found combined genetic testing for heritable cardiomyopathies and arrhythmias identified clinically relevant variants for one in five patients suspected of having one of these conditions. Two-thirds of the positive findin
Oct 26, 2021 07:30 am ET
Invitae to Announce Third Quarter 2021 Financial Results on Monday, November 8, 2021
SAN FRANCISCO, Oct. 26, 2021 /PRNewswire/ -- Invitae Corporation (NYSE: NVTA), a leading medical genetics company, today announced that it will report its third quarter 2021 financial results on Monday, November 8, 2021, and will host a conference call and webcast that day at 4:30 p.m. Eastern / 1:30 p.m. Pacific to discuss its financial results and recent highlights.
Oct 22, 2021 08:00 am ET
Invitae, UCL and the Francis Crick Institute Announce New Data From TRACERx Research Collaboration at the 2021 International Society of Liquid Biopsy Congress
SAN FRANCISCO, Oct. 22, 2021 /PRNewswire/ -- Invitae (NYSE: NVTA), University College London (UCL), and the Francis Crick Institute today announced new data from their TRACERx lung cancer research collaboration funded by Cancer Research UK and sponsored by UCL. The data, presented by Professor Charles Swanton of UCL and the Francis Crick Institute at the International Society of Liquid Biopsy (ISLB) Congress, further validate the value of liquid biopsy as a less invasive and more comprehensive approach to guiding personalized cancer treatment in the absence of detectable disease by clinical
Sep 25, 2021 12:15 pm ET
New Study Highlights the Value of Genetic Testing to Guide Clinical Management and Improve Outcomes for Epilepsy Patients
SAN FRANCISCO, Sept. 25, 2021 /PRNewswire/ -- Invitae (NYSE: NVTA), a leading medical genetics company, today presented research demonstrating that genetic findings informed clinical management changes that led to improved seizure control and outcomes in the majority of epilepsy patients with actionable findings. This study underscores the importance of genetic testing for all people with epilepsy and supports the growing evidence that medical genetic testing can improve health outcomes and reduce healthcare costs. The findings were presented at the National Society of Genetic Counselors 40t
Sep 14, 2021 07:30 am ET
Dante Labs Announces Expansion of its Finance Team with the Appointment of Andre Nel as Chief Financial Officer, Dalila Rahmani as Chief Accounting Officer, Laura D’Angelo as VP Investor Relations and
Dante Labs, a global leader in genomics and precision medicine, today announced the appointments of Andre Nel, Dalila Rahmani, Laura D’Angelo and Omar Elbakshish to the company’s management team, expanding its global leadership to help scale the...
Sep 07, 2021 07:00 am ET
Invitae to Acquire Ciitizen to Strengthen its Patient-Consented Health Data Platform to Improve Personal Outcomes and Global Research
SAN FRANCISCO, Sept. 7, 2021 /PRNewswire/ -- Invitae (NYSE: NVTA), a leading medical genetics company, today announced it has entered into a definitive agreement to acquire Ciitizen, a patient-centric consumer health tech company. Backed by a16z, Section 32 and Verily, Ciitizen is working to build a global platform to help patients collect, organize, store and share their medical records digitally. The acquisition would enhance Invitae's platform by providing patients an easy-to-use, centralized hub for their genomic and clinical information, which together comprise a powerful dataset with t
Sep 01, 2021 07:30 am ET
Invitae to Present at the Morgan Stanley 19th Annual Global Healthcare Conference
SAN FRANCISCO, Sept. 1, 2021 /PRNewswire/ -- Invitae Corporation (NYSE: NVTA), a leading medical genetics company, today announced that members of its management team will participate in a virtual fireside chat at the Morgan Stanley 19th Annual Global Healthcare Conference on Tuesday, September 14, 2021, at 12:30pm Eastern Time.
Aug 09, 2021 04:01 pm ET
Invitae to Present at the UBS Genomics 2.0 and MedTech Innovations Summit
SAN FRANCISCO, Aug. 9, 2021 /PRNewswire/ -- Invitae Corporation (NYSE: NVTA), a leading medical genetics company, today announced that members of its management team will participate in a fireside chat at the UBS Genomics 2.0 and MedTech Innovations Summit on Wednesday, August 11, 2021 at 11:00 a.m. PT and Sean George, chief executive officer of Invitae, will participate in the NGS Technologies panel presentation at 1:00 p.m. PT, both at Montage Laguna Beach.
Aug 09, 2021 08:30 am ET
Thinking about buying stock in Microvast, CTI BioPharma, Marathon Digital, Invitae Corp, or Riot Blockchain?
NEW YORK, Aug. 9, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for MVST, CTIC, MARA, NVTA, and RIOT.
Aug 04, 2021 08:45 am ET
Thinking about buying stock in Global Blood Therapeutics, Cerus Corp, Coursera, Agrify Corp, or Invitae Corp?
NEW YORK, Aug. 4, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for GBT, CERS, COUR, AGFY, and NVTA.
Aug 03, 2021 04:05 pm ET
Invitae Reports $116.3 Million in Revenue Driven by 287,000 in Billable Volume in Second Quarter of 2021
SAN FRANCISCO, Aug. 3, 2021 /PRNewswire/ -- Invitae Corporation (NYSE: NVTA), a leading medical genetics company, today announced preliminary financial and operating results for the second quarter ended June 30, 2021 and increases 2021 guide to revenue between $475-$500 million for the year.
Jul 22, 2021 08:00 am ET
Volpara Collaborates With Invitae Corporation, Leading Genetics Company
SEATTLE, July 22, 2021 /PRNewswire/ -- Volpara Health, a global health technology software leader providing an integrated breast care platform for the delivery of personalized breast care, has signed an agreement with Invitae Corporation, a leader in medical genetics, to bring Invitae's genetic testing services to Volpara's customers in the United States.
Jul 20, 2021 07:30 am ET
Invitae to Announce Second Quarter 2021 Financial Results on Tuesday, August 3, 2021
SAN FRANCISCO, July 20, 2021 /PRNewswire/ -- Invitae Corporation (NYSE: NVTA), a leading medical genetics company, today announced that it will report its second quarter 2021 financial results on Tuesday, August 3, 2021 and will host a conference call and webcast that day at 4:30 p.m. Eastern / 1:30 p.m. Pacific to discuss its financial results and recent highlights.
Jul 20, 2021 07:02 am ET
Pacific Biosciences and Invitae Announce Intent to Expand Collaboration
Pacific Biosciences of California, Inc. (Nasdaq: PACB)(“Pacific Biosciences” or “PacBio”), a leading provider of high-quality, long-read sequencing platforms, and Invitae Corporation (NYSE: NVTA), a leading medical genetics company, today announced...
Jun 22, 2021 08:00 am ET
OPKO Health Appoints Katherine Stueland as President and CEO of GeneDx
OPKO Health, Inc. (NASDAQ: OPK) today announced the appointment of Katherine Stueland as President and Chief Executive Officer of GeneDx, Inc., the global genomics subsidiary of OPKO’s BioReference Laboratories. Ms. Stueland joins GeneDx from...
Jun 11, 2021 07:30 am ET
Invitae appoints technology and medtech veteran Roxi Wen as chief financial officer
SAN FRANCISCO, June 11, 2021 /PRNewswire/ -- Invitae (NYSE: NVTA), a leading medical genetics company, today announced the appointment of Roxi Wen as its chief financial officer, effective June 21, 2021. Wen brings decades of success as a senior financial executive where she scaled global technology and medical technology companies.
Feb 24, 2021 06:30 am ET
Invitae adds Medneon's risk assessment tools to its education and clinical support offerings
SAN FRANCISCO, Feb. 24, 2021 /PRNewswire/ -- Invitae Corporation (NYSE: NVTA), a leading medical genetics company, today announced the addition of tools from Medneon, a digital health AI company, to its robust clinical workflow and patient education tools. The additional capabilities further support clinicians and patients with cancer by making it easier to determine who should get testing and how to use genetic information to individualize treatment.
Feb 23, 2021 06:30 am ET
Invitae expands capabilities of its advanced clinical chatbot Gia, enhancing telemedicine support for patients and clinicians
SAN FRANCISCO, Feb. 23, 2021 /PRNewswire/ -- Invitae Corporation (NYSE: NVTA), a leading medical genetics company, today announced expanded capabilities that enable clinicians to use its advanced clinical chatbot Gia to guide their patients in an intuitive, enjoyable and telemedicine-friendly conversation through receiving and understanding genetic test results and possible next steps, including scheduling a call with a genetics counselor.
Feb 22, 2021 03:05 pm ET
Invitae to Present at The Cowen 41st Annual Healthcare Conference
SAN FRANCISCO, Feb. 22, 2021 /PRNewswire/ -- Invitae Corporation (NYSE: NVTA), a leading medical genetics company, today announced that members of its management team will present at The Cowen 41st Annual Healthcare Conference on Tuesday, March 2, 2021 at 2:50 p.m. Eastern /11:50 a.m. Pacific.
Feb 17, 2021 03:05 pm ET
Invitae Reports $279.6 Million in Annual Revenue Driven by 659,000 in Billable Volume in 2020
SAN FRANCISCO, Feb. 17, 2021 /PRNewswire/ -- Invitae Corporation (NYSE: NVTA), a leading medical genetics company, today announced financial and operating results for the fourth quarter and full year ended December 31, 2020.
Feb 10, 2021 06:30 am ET
Invitae to Present at the 10th Annual SVB Leerink Global Healthcare Conference
SAN FRANCISCO, Feb. 10, 2021 /PRNewswire/ -- Invitae Corporation (NYSE: NVTA), a leading medical genetics company, today announced that members of its management team will present at the 10th Annual SVB Leerink Global Healthcare Conference on Wednesday, February 24, 2021 at noon Eastern/9:00 a.m. Pacific.
Feb 03, 2021 06:30 am ET
Invitae to Announce Fourth Quarter and Full Year 2020 Financial Results on Wednesday, February 17, 2021
SAN FRANCISCO, Feb. 3, 2021 /PRNewswire/ -- Invitae Corporation (NYSE: NVTA), a leading medical genetics company, today announced that it will report its fourth quarter and full year 2020 financial results on Wednesday, February 17, 2021 and will host a conference call and webcast that day at 4:30 p.m. Eastern / 1:30 p.m. Pacific to discuss its financial results and recent highlights.
Jan 26, 2021 03:05 pm ET
Invitae Announces Exercise in Full of Underwriters' Option to Purchase Additional Shares of Common Stock and Closing of Underwritten Public Offering
SAN FRANCISCO, Jan. 26, 2021 /PRNewswire/ -- Invitae Corporation (NYSE: NVTA) today announced the closing of its underwritten public offering of 8,932,038 shares of its common stock, including 1,165,048 shares sold pursuant to the exercise in full of the underwriters' option to purchase additional shares, at the public offering price of $51.50 per share. As a result of the underwriters' option exercise, the aggregate gross proceeds to Invitae from the offering, before deducting underwriting discounts and commissions and other offering expenses, was approximately $460.0 million.
Jan 21, 2021 07:37 pm ET
Invitae Announces Pricing of Public Offering of Common Stock
SAN FRANCISCO, Jan. 21, 2021 /PRNewswire/ -- Invitae Corporation (NYSE: NVTA) today announced the pricing of an underwritten public offering of 7,766,990 shares of its common stock at a price to the public of $51.50 per share. All of the shares are being sold by Invitae. The gross proceeds to Invitae from the offering, before deducting the underwriting discounts and commissions and other offering expenses, are expected to be approximately $400.0 million. The offering is expected to close on or about January 26, 2021, subject to customary closing conditions. In addition, Invitae has granted t
Jan 20, 2021 03:05 pm ET
Invitae Announces Proposed Public Offering of Common Stock
SAN FRANCISCO, Jan. 20, 2021 /PRNewswire/ -- Invitae Corporation (NYSE: NVTA) today announced that it has commenced an underwritten public offering of $400.0 million of shares of its common stock, before deducting underwriting discounts and commissions and other offering expenses. All of the shares are being offered by Invitae. In addition, Invitae expects to grant the underwriters a 30-day option to purchase up to an additional $60.0 million of shares of its common stock at the public offering price, less underwriting discounts and commissions. The offering is subject to market and other co
Jan 14, 2021 06:30 am ET
Leading Biopharmaceutical Companies Select Invitae to Develop Standardized Panel to Detect Molecular Residual Disease (MRD) in Patients with Acute Myeloid Leukemia (AML)
SAN FRANCISCO, Jan. 14, 2021 /PRNewswire/ -- Invitae Corporation (NYSE: NVTA), a leading medical genetics company, today announced the launch of a new project with Bristol Myers Squibb, Janssen Research & Development, LLC (Janssen), Novartis and Genentech, a member of the Roche Group, to develop a standardized panel for MRD detection in patients with AML to support clinical trial testing across multiple drug development programs. The companies are working together to standardize how MRD data is generated and assessed in clinical trials helping to better establish the clinical utility of
Jan 13, 2021 08:02 am ET
Pacific Biosciences and Invitae to Develop Ultra-High-Throughput Clinical Whole Genome Sequencing Platform
Pacific Biosciences of California, Inc. (Nasdaq: PACB), a leading provider of high-quality, long-read sequencing platforms, today announced a multi-year collaboration with Invitae Corporation (NYSE: NVTA), a leading medical genetics company, to...
Jan 11, 2021 06:30 am ET
Invitae Reports Preliminary 2020 Financial Results of More Than $278 Million in Revenue and More Than 655,000 in Billable Volume
SAN FRANCISCO, Jan. 11, 2021 /PRNewswire/ -- Invitae Corporation (NYSE: NVTA), a leading medical genetics company, announced preliminary unaudited full-year 2020 results, reporting strong growth in volume and revenue, signaling continued momentum into 2021.
Dec 29, 2020 06:30 am ET
Invitae to Present at the 39th Annual J.P. Morgan Healthcare Conference
SAN FRANCISCO, Dec. 29, 2020 /PRNewswire/ -- Invitae Corporation (NYSE: NVTA), a leading medical genetics company, today announced that Sean George, co-founder and chief executive officer of Invitae, will present at the 39th Annual J.P. Morgan Healthcare Conference on Tuesday, January 12, 2021 at 10:50 a.m. Eastern/7:50 a.m. Pacific. Following the company presentation, management will participate in a virtual breakout session at 11:10 a.m. Eastern/8:10 a.m. Pacific.
Dec 17, 2020 06:30 am ET
Invitae Introduces Routine Exome Reanalysis to Help Patients Receive Diagnoses Faster
SAN FRANCISCO, Dec. 17, 2020 /PRNewswire/ -- Invitae (NYSE: NVTA), a leading medical genetics company, today announced all patients who undergo exome testing with Invitae will receive routine case-level reanalysis of their findings every six months for at least three years. Reanalysis ensures patients' reports will be regularly updated based on new research about links between variants in their genes and their health -- an essential step for people grappling with difficult-to-diagnose health problems.
Dec 09, 2020 06:30 am ET
Invitae to Present New Data Supporting Genetic Testing for All Breast Cancer Patients at the 2020 San Antonio Breast Cancer Symposium
SAN FRANCISCO, Dec. 9, 2020 /PRNewswire/ -- Invitae (NYSE: NVTA), a leading medical genetics company, today announced three studies demonstrating the benefits of genetic testing for all breast cancer patients, impacting treatment decisions and cancer screening for patients and their families. The studies, which will be presented at the 2020 San Antonio Breast Cancer Symposium (SABCS), add to the evidence supporting universal access to genetic information for all breast cancer patients.
Nov 19, 2020 09:57 am ET
New Study Highlights the Importance of Genetic Testing for Pancreatic Cancer Patients
SAN FRANCISCO, Nov. 19, 2020 /CNW/ -- Invitae (NYSE: NVTA), a leading medical genetics company, today presented study findings that show nine percent of patients with pancreatic cancer had genetic changes in DNA damage repair (DDR) genes that would make them eligible for PARP inhibitor therapy or clinical treatment trials. Despite professional guidelines that recommend testing for all pancreatic cancer patients, it remains underutilized in routine care. The study was presented at the National Society of Genetic Counselors 39th Annual Conference.
Nov 19, 2020 09:57 am ET
New Study Highlights the Importance of Genetic Testing for Pancreatic Cancer Patients
SAN FRANCISCO, Nov. 19, 2020 /PRNewswire/ -- Invitae (NYSE: NVTA), a leading medical genetics company, today presented study findings that show nine percent of patients with pancreatic cancer had genetic changes in DNA damage repair (DDR) genes that would make them eligible for PARP inhibitor therapy or clinical treatment trials. Despite professional guidelines that recommend testing for all pancreatic cancer patients, it remains underutilized in routine care. The study was presented at the National Society of Genetic Counselors 39th Annual Conference.
Nov 09, 2020 07:00 am ET
Passage Bio and Invitae Announce Collaboration to Facilitate Genetic Testing to Support Early Diagnosis and Greater Awareness of Clinical Trials for Patients with GM1
Passage Bio, Inc. (NASDAQ: PASG), a genetic medicines company focused on developing transformative therapies for rare, monogenic central nervous system disorders, and Invitae (NYSE: NVTA), a leading medical genetics company, announce a...
Nov 05, 2020 03:05 pm ET
Invitae Reports $68.7 Million in Revenue Driven by 170,000 Samples Accessioned in the Third Quarter of 2020
SAN FRANCISCO, Nov. 5, 2020 /PRNewswire/ -- Invitae Corporation (NYSE: NVTA), a leading medical genetics company, today announced financial and operating results for the third quarter ended September 30, 2020.
Oct 28, 2020 07:30 am ET
Research Highlights Frequency of Genetic Risk Factors Among Men with Prostate Cancer, Suggests Role for Broader Screening
— Three-quarters of patients with genetic changes had clinically relevant findings, including eligibility for precision therapies —
Oct 28, 2020 07:30 am ET
Research Highlights Frequency of Genetic Risk Factors Among Men with Prostate Cancer, Suggests Role for Broader Screening
— Three-quarters of patients with genetic changes had clinically relevant findings, including eligibility for precision therapies —
Oct 23, 2020 07:30 am ET
Invitae to Announce Third Quarter 2020 Financial Results on Thursday, November 5, 2020
SAN FRANCISCO, Oct. 23, 2020 /PRNewswire/ -- Invitae Corporation (NYSE: NVTA), a leading medical genetics company, today announced that it will report its third quarter 2020 financial results on Thursday, November 5, 2020 and will host a conference call and webcast that day at 4:30 p.m. Eastern / 1:30 p.m. Pacific to discuss its financial results and recent highlights.
Oct 22, 2020 08:00 am ET
Invitae and Pacific Biosciences Collaborate to Develop Whole Genome Sequencing-Based Assays for Pediatric Epilepsy Diagnostics
Invitae Corporation (NYSE: NVTA), a leading genetics company, and Pacific Biosciences of California, Inc. (Nasdaq:PACB), a leading provider of high-quality sequencing of genomes, transcriptomes and epigenomes, today announced a research...
Aug 04, 2020 06:37 pm ET
Invitae Reports Inducement Grants Under NYSE Rule 303A.08
SAN FRANCISCO, Aug. 4, 2020 /PRNewswire/ -- Invitae Corporation (NYSE: NVTA), a leading medical genetics company, today announced that it granted restricted stock units ("RSUs") to Kenneth D. Knight, Invitae's new Chief Operating Officer and Karthik Suri, Invitae's new Chief Digital Officer. The RSUs were granted under Invitae's 2015 Stock Incentive Plan, which was amended and restated to create an additional pool of 475,000 shares of Invitae common stock to be used exclusively for the grant of inducement awards in compliance with New York Stock Exchange Rule 303A.08 ("Rule 303A.08"). The RS
Aug 04, 2020 04:05 pm ET
Invitae Reports $46.2 Million in Revenue Driven by More Than 120,000 Samples Accessioned in the Second Quarter of 2020
SAN FRANCISCO, Aug. 4, 2020 /PRNewswire/ -- Invitae Corporation (NYSE: NVTA), a leading medical genetics company, today announced financial and operating results for the second quarter ended June 30, 2020.
Jul 21, 2020 07:05 am ET
Invitae to Announce Second Quarter 2020 Financial Results on August 4, 2020
SAN FRANCISCO, July 21, 2020 /PRNewswire/ -- Invitae Corporation (NYSE: NVTA), a leading medical genetics company, today announced that it will report its second quarter 2020 financial results on Tuesday, August 4, 2020 and will host a conference call and webcast that day at 4:30 p.m. Eastern / 1:30 p.m. Pacific to discuss its financial results and recent highlights.
Jul 08, 2020 01:19 pm ET
Moore Kuehn Encourages DCOM, MYOS, ADSW, and NVTA Investors to Contact Law Firm
NEW YORK, July 8, 2020 /PRNewswire/ -- Moore Kuehn, PLLC, a law firm focusing in securities litigation located on Wall Street in downtown New York City, is investigating potential claims concerning whether the following proposed mergers are fair to shareholders. Moore Kuehn may ultimately seek increased consideration, additional disclosures, or other relief and benefits on behalf of the shareholders of these companies:
Jul 06, 2020 05:15 pm ET
MERGER ALERT - ADSW, MYOS, NVTA : Levi & Korsinsky, LLP Reminds Investors of Investigations Concerning the Mergers of these Companies
NEW YORK, NY / ACCESSWIRE / July 6, 2020 / The following statement is being issued by Levi & Korsinsky, LLP:
Jul 02, 2020 11:10 am ET
MERGER ALERT - ADSW, IFF, NVTA : Levi & Korsinsky, LLP Reminds Investors of Investigations Concerning the Mergers of these Companies
NEW YORK, NY / ACCESSWIRE / July 2, 2020 / The following statement is being issued by Levi & Korsinsky, LLP: Levi & Korsinsky, LLP announces that investigations have commenced on behalf of shareholders of the following publicly-traded companies.
Jul 01, 2020 06:48 pm ET
INVITAE INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Invitae Corporation - NVTA
Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed merger of Invitae Corporation (NYSE: NVTA) (“the Company”) with ArcherDX in a stock-for-stock transaction. KSF is seeking to determine whether the merger and the process that led to it are adequate, or whether the merger undervalues the Company.
Jun 26, 2020 10:28 pm ET
Invitae Merger Investigation: Halper Sadeh LLP Announces Investigation Into Whether The Merger Of Invitae Corporation Is Fair To Shareholders; Investors Are Encouraged To Contact The Firm
NEW YORK, June 26, 2020 /PRNewswire/ -- Halper Sadeh LLP, a global investor rights law firm, is investigating whether the merger between Invitae Corporation (NYSE: NVTA) and ArcherDX is fair to Invitae shareholders. On behalf of Invitae shareholders, Halper Sadeh LLP may seek increased consideration for shareholders, additional disclosures and information concerning the proposed transaction, or other relief and benefits.
Jun 25, 2020 09:31 am ET
Thinking about trading options or stock in InVitae Corp, Penn National Gaming, Ford Motor Company, Bank of America, or Advanced Micro Devices?
NEW YORK, June 25, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for NVTA, PENN, F, BAC, and AMD.
Jun 22, 2020 09:31 am ET
Thinking about buying stock in Microvision, InVitae Corp, Alpine Immune Sciences, Anavex Life Sciences, or Ford Motor?
NEW YORK, June 22, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for MVIS, NVTA, ALPN, AVXL, and F.
Jun 22, 2020 07:00 am ET
Invitae and ArcherDX to create a global leader in comprehensive cancer genetics and precision oncology
SAN FRANCISCO and BOULDER, Colo., June 22, 2020 /PRNewswire/ -- Invitae (NYSE: NVTA), a leading genetics company, and ArcherDX, a leading genomics analysis company democratizing precision oncology, today announced the companies have entered into a definitive agreement under which Invitae will combine with ArcherDX to create a genetics leader with unrivaled breadth and scale in cancer genetics and precision oncology.
Jun 11, 2020 07:30 am ET
Recent Research And New Multidisciplinary Framework For Genetic Testing In Prostate Cancer Supports Broader Use Of Panels, Testing In Early Stage Disease
SAN FRANCISCO, June 11, 2020 /PRNewswire/ -- New recommendations from a large, multidisciplinary consensus conference published this week in the Journal of Clinical Oncology suggest expanding use of genetic testing to guide treatment for men with prostate cancer, including the use of panel testing and testing patients with early stage disease. Taken together with research recently presented by Invitae (NYSE: NVTA), a leading genetics company, the publications underscore the utility of increased access to genetic testing for men with prostate cancer across all stages of disease.
May 28, 2020 07:30 am ET
Invitae to Present at the William Blair 40th Annual Growth Stock Conference
SAN FRANCISCO, May 28, 2020 /PRNewswire/ -- Invitae Corporation (NYSE: NVTA), a leading medical genetics company, today announced that members of its management team will virtually present at the William Blair 40th Annual Growth Stock Conference on Thursday, June 11, 2020 at 9:20 a.m. Central / 7:20 a.m. Pacific.
May 07, 2020 07:30 am ET
Invitae makes it easier for consumers to access medical genetic tests in Canada
-- Online service offers high-quality testing for genetic health risks --
May 07, 2020 07:30 am ET
Invitae makes it easier for consumers to access medical genetic tests in Canada
-- Online service offers high-quality testing for genetic health risks --
May 05, 2020 04:05 pm ET
Invitae Reports More Than $64 Million in Revenue Driven by More Than 154,000 Samples Accessioned in the First Quarter of 2020
SAN FRANCISCO, May 5, 2020 /PRNewswire/ -- Invitae Corporation (NYSE: NVTA), a leading medical genetics company, today announced financial and operating results for the first quarter ended March 31, 2020.
Apr 21, 2020 04:05 pm ET
Invitae to announce first quarter 2020 financial results on May 5, 2020
SAN FRANCISCO, April 21, 2020 /PRNewswire/ -- Invitae Corporation (NYSE: NVTA), a leading medical genetics company, today announced that it will report its first quarter 2020 financial results on Tuesday, May 5, 2020 and will host a conference call and webcast that day at 4:30 p.m. Eastern / 1:30 p.m. Pacific to discuss its financial results and recent highlights.
Apr 15, 2020 08:00 am ET
Axovant Announces Partnership with Invitae to Increase Access to Genetic Testing and Accelerate Diagnoses of GM1 and GM2 Gangliosidosis
Axovant Gene Therapies Ltd., a clinical-stage company developing innovative gene therapies for neurological diseases, today announced its collaboration with Invitae, a leading medical genetics company, in the Detect Lysosomal Storage Diseases...
Apr 07, 2020 07:30 am ET
Invitae launches enhanced capabilities to support telemedicine
SAN FRANCISCO, April 7, 2020 /PRNewswire/ -- Invitae (NYSE: NVTA), a leading medical genetics company today announced new tools to help obstetrician/gynecologists, oncologists, genetic counselors and other clinicians who order genetic tests via telemedicine for women and couples early in pregnancy and for patients with cancer. Invitae's advanced clinical chatbot, Gia, provides an end-to-end telemedicine genetic testing framework that helps identify patients who need germline genetic testing.
Apr 06, 2020 04:05 pm ET
Invitae Announces Exercise in Full of Underwriters' Option to Purchase Additional Shares of Common Stock and Closing of Underwritten Public Offering
SAN FRANCISCO, April 6, 2020 /PRNewswire/ -- Invitae Corporation (NYSE: NVTA) today announced the closing of its underwritten public offering of 20,444,444 shares of its common stock, including 2,666,666 shares sold pursuant to the exercise in full of the underwriters' option to purchase additional shares, at the public offering price of $9.00 per share. As a result of the underwriters' option exercise, the aggregate gross proceeds to Invitae from the offering, before deducting underwriting discounts and commissions and other offering expenses, was approximately $184.0 million.
Apr 01, 2020 10:48 pm ET
Invitae Announces Pricing of Public Offering of Common Stock
SAN FRANCISCO, April 1, 2020 /PRNewswire/ -- Invitae Corporation (NYSE: NVTA) today announced the pricing of an underwritten public offering of 17,777,778 shares of its common stock at a price to the public of $9.00 per share. All of the shares are being sold by Invitae. The gross proceeds to Invitae from the offering, before deducting the underwriting discounts and commissions and other offering expenses, are expected to be approximately $160.0 million. The offering is expected to close on or about April 6, 2020, subject to customary closing conditions. In addition, Invitae has granted the
Apr 01, 2020 04:17 pm ET
Invitae Announces Proposed Public Offering of Common Stock
SAN FRANCISCO, April 1, 2020 /PRNewswire/ -- Invitae Corporation (NYSE: NVTA) today announced that it has commenced an underwritten public offering of $125.0 million of shares of its common stock, before deducting underwriting discounts and commissions and other offering expenses. All of the shares are being offered by Invitae. In addition, Invitae expects to grant the underwriters a 30-day option to purchase up to an additional $18.75 million of shares of its common stock at the public offering price, less underwriting discounts and commissions. The offering is subject to market and other c
Mar 23, 2020 07:30 am ET
Invitae and Muscular Dystrophy Association (MDA) Expand Access to No-Charge Genetic Testing in the U.S. and Canada
SAN FRANCISCO, March 23, 2020 /PRNewswire/ -- Invitae (NYSE: NVTA), a leading medical genetics company today announced its partnership with the Muscular Dystrophy Association (MDA) to offer sponsored, no-charge genetic testing to patients through the Detect Muscular Dystrophy program in MDA's care center network, a network of clinics at more than 150 of the nation's top healthcare institutions.
Nov 11, 2019 06:30 am ET
Invitae to Acquire Clear Genetics
SAN FRANCISCO, Nov. 11, 2019 /PRNewswire/ -- Invitae Corporation (NYSE: NVTA), a leading medical genetics company, today announced it has entered into a definitive agreement to acquire Clear Genetics, a leading developer of software for providing genetic services at scale. Using intuitive chatbots, Clear Genetics equips patients with actionable information throughout the genetic testing process and provides guidance for understanding test results. The acquisition will further expand Invitae's ability to scale and deliver genetic information as a part of routine medical care.
Nov 08, 2019 04:59 pm ET
University of Vermont Health Network begins offering Genomic DNA Testing
BURLINGTON, Vt., Nov. 8, 2019 /PRNewswire/ -- The University of Vermont Health Network has begun a pilot project to offer Genomic DNA Testing to patients as part of their clinical care. The pilot program is the beginning of an effort to increase the integration of genetic disease risks into routine medical care, which holds promise for providing Vermonters with valuable information to guide their health decisions.
Nov 06, 2019 03:05 pm ET
Invitae Reports $56.5 Million in Quarterly Revenue Driven by 129,000 Samples
SAN FRANCISCO, Nov. 6, 2019 /PRNewswire/ -- Invitae Corporation (NYSE: NVTA), a leading medical genetics company, today announced financial and operating results for the third quarter ended September 30, 2019.
Nov 05, 2019 06:30 am ET
Invitae Highlights Importance of Medical Genetics, Honors Excellence in Genetic Counseling at National Society of Genetic Counselors (NSGC) 38th Annual Conference
SALT LAKE CITY, Nov. 5, 2019 /PRNewswire/ -- Researchers from Invitae Corporation (NYSE: NVTA), a leading medical genetics company, are presenting research this week at the National Society of Genetic Counselors (NSGC) 37th Annual Conference in Atlanta that helps push forward the science and practice of genetics in patient care. In addition to its research presentations, the company is supporting the Code Talker award, which recognizes excellence in the field of genetic counseling.
Oct 23, 2019 07:30 am ET
Invitae to announce third quarter 2019 financial results on November 6, 2019
SAN FRANCISCO, Oct. 23, 2019 /PRNewswire/ -- Invitae Corporation (NYSE: NVTA), a leading medical genetics company, today announced that it will report its third quarter 2019 financial results on Wednesday, November 6, 2019 and will host a conference call and webcast that day at 4:30 p.m. Eastern / 1:30 p.m. Pacific to discuss its financial results and recent highlights.
Oct 17, 2019 07:30 am ET
Research presented by Invitae at the American Society of Human Genetics Meeting Pushes Science and Practice of Genetics Forward
HOUSTON, Oct. 17, 2019 /PRNewswire/ -- Researchers from Invitae Corporation (NYSE: NVTA), a leading medical genetics company, are presenting data showing the increasing utility of genetic information at the American Society of Human Genetics (ASHG) annual meeting this week, ranging from comprehensive screening for cancer patients, to appropriate clinical follow up for women using non-invasive prenatal screening, to the limitations of direct to consumer genetic screening health reports.
Sep 09, 2019 07:30 am ET
Invitae Expands Detect Program to Offer No-Charge Genetic Testing to Pancreatic Cancer Patients
SAN FRANCISCO, Sept. 9, 2019 /PRNewswire/ -- Invitae (NYSE: NVTA), a leading medical genetics company, today announced the availability of Detect Hereditary Pancreatic Cancer, a testing program that offers no-charge genetic testing and counseling to patients with pancreatic cancer. Genetic testing is recommended by clinicians for all pancreatic cancer patients to guide treatment choices and evaluate eligibility for clinical trials.
Sep 06, 2019 07:00 am ET
Invitae Prices Upsized Offering of $300 Million of Convertible Senior Notes
SAN FRANCISCO, Sept. 6, 2019 /PRNewswire/ -- Invitae Corporation (NYSE: NVTA) announced the pricing on September 5, 2019 of $300.0 million aggregate principal amount of 2.00% convertible senior notes due 2024 (the "notes") in a private offering to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the "Securities Act"). The aggregate principal amount of the offering was increased from the previously announced offering size of $200.0 million. Invitae granted the initial purchasers of the notes a 13-day option to purchase up to an additional $50.
Sep 04, 2019 04:05 pm ET
Invitae Announces Proposed Offering of $200 Million of Convertible Senior Notes
SAN FRANCISCO, Sept. 4, 2019 /PRNewswire/ -- Invitae Corporation (NYSE: NVTA) today announced its intention to offer, subject to market conditions and other factors, $200.0 million aggregate principal amount of convertible senior notes due 2024 (the "notes") in a private offering to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the "Securities Act"). In connection with the offering, Invitae expects to grant the initial purchasers of the notes a 13-day option to purchase up to an additional $30.0 million principal amount of notes on the sam
Aug 20, 2019 07:30 am ET
Biogen and Invitae Announce Availability of Rapid Results in Genetic Testing Program for Spinal Muscular Atrophy (SMA) to Improve Speed of Diagnosis for Patients
Biogen Inc. (Nasdaq: BIIB) and Invitae Corporation (NYSE: NVTA) today announced that SMA STAT, a new, rapid-turnaround genetic test for spinal muscular atrophy (SMA), will be offered at no charge to individuals in the U.S. as part of the SMA...
Aug 06, 2019 04:15 pm ET
Invitae Reports $53.5 Million in Quarterly Revenue Driven by More Than 111,000 Samples in Quarterly Volume
SAN FRANCISCO, Aug. 6, 2019 /PRNewswire/ -- Invitae Corporation (NYSE: NVTA), a leading medical genetics company, today announced financial and operating results for the second quarter ended June 30, 2019.
Jul 24, 2019 07:30 am ET
Invitae Launches Detect Programs to Make it Easier for Patients to Get Genetic Testing for Prostate Cancer, Muscular Dystrophy and Heart Conditions
SAN FRANCISCO, July 24, 2019 /PRNewswire/ -- Invitae (NYSE: NVTA), a leading medical genetics company, today announced the availability of its Detect programs to provide no-charge genetic testing for conditions in which testing is underutilized and can improve diagnosis and treatment. Research has shown no-charge testing programs result in earlier diagnosis and treatment. Enrollment is now open for Detect programs in four conditions: muscular dystrophy, prostate cancer, cardiomyopathy and arrhythmia and lysosomal storage diseases.
Jul 23, 2019 07:30 am ET
Invitae to announce second quarter 2019 financial results on August 6, 2019
SAN FRANCISCO, July 23, 2019 /PRNewswire/ -- Invitae Corporation (NYSE: NVTA), a leading medical genetics company, today announced that it will report its second quarter 2019 financial results on Tuesday, August 6, 2019 and will host a conference call and webcast that day at 4:30 p.m. Eastern / 1:30 p.m. Pacific to discuss its financial results and recent highlights.
Jul 11, 2019 04:06 pm ET
Invitae to Acquire Jungla to Advance Genetic Variant Interpretation, Adds Supplemental RNA Analysis to Deliver Deeper, More Informative Results to Patients
SAN FRANCISCO, July 11, 2019 /PRNewswire/ -- Invitae Corporation (NYSE: NVTA), a leading medical genetics company, today announced it has entered into a definitive agreement to acquire Jungla Inc., a privately held company funded by Andreessen Horowitz (a16z) that has developed a cloud-based platform that combines clinical knowledge with advances in functional genomics, biophysics, cellular engineering, machine learning, and distributed systems to help clinicians and patients understand the results of genetic and genomic tests. The combination is expected to further enhance Invitae's genetic
Jun 27, 2019 02:00 pm ET
Capital Market Laboratories (CMLviz) Interviews Invitae’s CEO –Invitae’s Non-Invasive Prenatal Screening Tests Can be a 50% Gross Margin Business
In an interview with Capital Market Laboratories (CMLviz), chief executive officer of Invitae (NYSE:NVTA) Sean George had a clear message: Invitae will never be announcing M&A in an attempt to fill a drop-in revenue. The acquisition of Singular Bio...
Jun 12, 2019 08:30 am ET
X4 Pharmaceuticals and Invitae Announce Partnership to Provide No-Cost Genetic Testing to Patients Suspected of Primary Immunodeficiency Disease
X4
Pharmaceuticals, Inc. (Nasdaq: XFOR), a clinical-stage
biopharmaceutical company focused on the development of novel
therapeutics for the treatment of rare diseases, and Invitae Corporation
(NYSE: NVTA), a leader in medical genetics, today announced a
partnership to provide genetic testing at no cost to patients th
May 29, 2019 08:00 am ET
Horizon Therapeutics plc and Invitae Corporation Launch Urea Cycle Disorder Genetic Testing Program
Horizon Therapeutics plc (Nasdaq: HZNP) in partnership with Invitae
Corporation (NYSE: NVTA) today announced a new urea cycle disorder (UCD)
genetic testing program designed to speed diagnosis and enable
physicians to offer genetic testing at no-charge to people who may have
a UCD, including their family members. Horizon’s support of the UCD
Genetic Testing Program facilitates the genetic tests and services
offered and performed by Invitae.
May 22, 2019 07:30 am ET
Invitae to Present at the 2019 William Blair Growth Stock Conference
SAN FRANCISCO, May 22, 2019 /PRNewswire/ -- Invitae Corporation (NYSE: NVTA), a leading medical genetics company, today announced that Sean George, co-founder and chief executive officer of Invitae will present at the 2019 William Blair Growth Stock Conference on Wednesday, June 5, 2019 at 2:40 p.m. Central / 12:40 p.m. Pacific in Chicago.
May 15, 2019 07:30 am ET
Invitae to Present at the UBS Global Healthcare Conference
SAN FRANCISCO, May 15, 2019 /PRNewswire/ -- Invitae Corporation (NYSE: NVTA), the leader in advanced medical genetics, today announced that Sean George, co-founder and chief executive officer of Invitae, will present at the UBS Global Healthcare Conference on Wednesday, May 22, 2019 at 10:30 a.m. Eastern / 7:30 a.m. Pacific in New York City.
May 07, 2019 04:05 pm ET
Invitae Reports 47% Growth in Quarterly Revenue and Volume Year-Over-Year
SAN FRANCISCO, May 7, 2019 /PRNewswire/ -- Invitae Corporation (NYSE: NVTA), the leader in advanced medical genetics, today announced financial and operating results for the first quarter ended March 31, 2019.
May 03, 2019 07:30 am ET
New Study From Invitae Highlights the Importance of Multigene Genetic Testing for Uterine Cancer Patients
SAN FRANCISCO, May 3, 2019 /PRNewswire/ -- Researchers from Invitae (NYSE: NVTA), a leading genetics company, will present a study of more than 6,500 patients with uterine cancer showing that genetic testing provided more than 80 percent of patients with information that made them eligible for precision medicine therapies. The study also highlighted the importance of multigene panel testing versus traditional, limited approaches and was presented this week at the 2019 American College of Obstetricians and Gynecologists (ACOG) Annual Clinical and Scientific Meeting.
Apr 23, 2019 07:30 am ET
Invitae to announce first quarter 2019 financial results on May 7, 2019
SAN FRANCISCO, April 23, 2019 /PRNewswire/ -- Invitae Corporation (NYSE: NVTA), a leading genetics company, today announced that it will report its first quarter 2019 financial results on Tuesday, May 7, 2019 and will host a conference call and webcast that day at 4:30 p.m. Eastern / 1:30 p.m. Pacific to discuss its financial results and recent highlights.
Apr 11, 2019 08:16 am ET
FH Foundation Expands FIND FH® to Speed Diagnosis of Individuals with Homozygous Familial Hypercholesterolemia
PASADENA, Calif., April 11, 2019 /PRNewswire/ -- Today, the FH Foundation announced the launch of the FIND HoFH program to identify individuals at risk for homozygous familial hypercholesterolemia (HoFH). The goal is to accelerate the diagnosis of this life-threatening condition. HoFH is a more severe form of familial hypercholesterolemia (FH), that can lead to heart disease, heart attacks and aortic valve disease in children and young adults. Individuals identified through the program will have the option to receive genetic counseling and confirmatory genetic testing through a collaboration
Apr 02, 2019 07:30 am ET
Research Underscores Need for Updated Guidelines to Include Multigene Testing for Cancer Patients
SAN FRANCISCO, April 2, 2019 /PRNewswire/ -- Researchers from Invitae (NYSE: NVTA), a leading genetics company, will present data from more than 113,000 patients that support updating genetic testing guidelines to include clear recommendations for multigene panel testing in patients with cancer. According to the study, patients with ovarian, breast, pancreatic, prostate and colorectal cancer with potentially actionable germline variants are being missed each year when clinicians adhere to guidelines that restrict testing to one or a few gene panels.
Mar 14, 2019 07:30 am ET
Invitae to Present at the Oppenheimer 29th Annual Healthcare Conference
SAN FRANCISCO, March 14, 2019 /PRNewswire/ -- Invitae Corporation (NYSE: NVTA), a leading genetics company, today announced that Sean George, co-founder and chief executive officer of Invitae, will present at the Oppenheimer 29th Annual Healthcare Conference on Wednesday, March 20, 2019 at 1:35 p.m. Eastern / 10:35 a.m. Pacific in New York City.
Mar 07, 2019 07:30 am ET
Recent Analysis Shows Invitae, Check Point Software Technologies, Ebix, CenturyLink, Republic Services, and Costamare Market Influences — Renewed Outlook, Key Drivers of Growth
In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of Invitae Corporation (NYSE:NVTA), Check Point Software Technologies Ltd....
Mar 06, 2019 08:31 pm ET
Invitae Announces Exercise in Full of Underwriters' Option to Purchase Additional Shares of Common Stock
SAN FRANCISCO, March 6, 2019 /PRNewswire/ -- Invitae Corporation (NYSE: NVTA) today announced the exercise in full of the underwriters' option to purchase an additional 1,350,000 shares of its common stock at the public offering price of $19.00 per share, in connection with Invitae's recently announced underwritten public offering of 9,000,000 shares of its common stock. As a result of the underwriters' option exercise, the aggregate gross proceeds to Invitae from the offering, before deducting the underwriting discounts and commissions and other offering expenses, are expected to be approxi
Mar 05, 2019 07:19 pm ET
Invitae Announces Pricing of Public Offering of Common Stock
SAN FRANCISCO, March 5, 2019 /PRNewswire/ -- Invitae Corporation (NYSE: NVTA) today announced the pricing of an underwritten public offering of 9,000,000 shares of its common stock at a price to the public of $19.00 per share. All of the shares are being sold by Invitae. The gross proceeds to Invitae from the offering, before deducting the underwriting discounts and commissions and other offering expenses, are expected to be $171.0 million. The offering is expected to close on or about March 8, 2019, subject to customary closing conditions. In addition, Invitae has granted the underwriters a
Mar 04, 2019 03:07 pm ET
Invitae Announces Proposed Public Offering of Common Stock
SAN FRANCISCO, March 4, 2019 /PRNewswire/ -- Invitae Corporation (NYSE: NVTA) today announced that it has commenced an underwritten public offering of $125.0 million of shares of its common stock, before deducting underwriting discounts and commissions and other offering expenses. All of the shares are being offered by Invitae. In addition, Invitae expects to grant the underwriters a 30-day option to purchase up to an additional $18.75 million of shares of its common stock at the public offering price, less underwriting discounts and commissions. The offering is subject to market and other c
Feb 26, 2019 06:30 am ET
Behind the Seizure™ Program Expansion Helps Speed the Diagnosis of Genetic Epilepsy in Younger Children Experiencing Unprovoked Seizures
SAN FRANCISCO, Feb. 26, 2019 /PRNewswire/ -- As Rare Disease Day focuses attention on the challenges of diagnosing rare, often genetic conditions, BioMarin Pharmaceutical Inc. (NASDAQ: BMRN), Invitae Corporation (NYSE: NVTA), Stoke Therapeutics and Xenon Pharmaceuticals (NASDAQ: XENE) today announced the expansion of Behind the Seizure, an innovative, cross-company collaboration that aims to provide faster diagnosis for young children with epilepsy. Previously available to patients ages 2-4 years, the program will expand eligibility to make no-cost genetic testing available for healthcare pr
Feb 19, 2019 03:05 pm ET
Invitae More Than Doubles Annual Volume and Revenue Year-Over-Year, Delivering 117% in Revenue Growth Driven by 102% Growth in Volume in 2018
SAN FRANCISCO, Feb. 19, 2019 /PRNewswire/ -- Invitae Corporation (NYSE: NVTA), a leading genetics company, today announced financial and operating results for the fourth quarter and full year ended December 31, 2018.
Feb 13, 2019 07:45 am ET
Recent Analysis Shows General Mills, Paycom Software, Invitae, Jagged Peak Energy, John B. Sanfilippo & Son, and Intrepid Potash Market Influences — Renewed Outlook, Key Drivers of Growth
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of General Mills, Inc. (NYSE:GIS), Paycom Software, Inc. (NYSE:PAYC), Invitae...
Feb 13, 2019 06:30 am ET
Invitae to Present at the 8th Annual SVB Leerink Global Healthcare Conference
SAN FRANCISCO, Feb. 13, 2019 /PRNewswire/ -- Invitae Corporation (NYSE: NVTA), a leading genetics company, today announced that Sean George, co-founder and chief executive officer of Invitae, will present at the 8th Annual SVB Leerink Global Healthcare Conference on Wednesday, February 27, 2019 at 11:30 a.m. Eastern / 8:30 a.m. Pacific in New York City.
Feb 12, 2019 06:30 am ET
Invitae Launches Non-Invasive Prenatal Screening (NIPS), Offering In-Depth Genetic Information in Early Pregnancy
SAN FRANCISCO, Feb. 12, 2019 /PRNewswire/ -- Invitae Corporation (NYSE: NVTA), a leading genetics company, today announced the addition of non-invasive prenatal screening (NIPS) to the company's comprehensive women's health genetic testing services, providing patients with easier access to affordable genetic testing in early pregnancy. In combination with the expanded carrier screening (ECS), Invitae now offers integrated testing using the two most common prenatal genetic tests, with in-depth follow-up testing available for patients who need it. The company made the announcement in conjuncti
Feb 07, 2019 11:00 am ET
New Study Finds Disease-Causing Variants More Common in Men with Prostate Cancer Than Previously Thought
SAN FRANCISCO, Feb. 7, 2019 /PRNewswire/ -- The largest study to date on the genetics of prostate cancer has found that 17 percent of prostate cancer patients are born with genetic variants that can be associated with higher risk of various cancers. The study was published today in JAMA Oncology by researchers from Tulane Cancer Center and Invitae (NYSE: NVTA), a leading genetics company. In addition, the analysis found that guidelines for genetic testing at the time of the study missed a substantial number of patients, suggesting broader testing is warranted.
Jan 29, 2019 06:30 am ET
Invitae to announce fourth quarter and year-end 2018 financial results on February 19, 2019
SAN FRANCISCO, Jan. 29, 2019 /PRNewswire/ -- Invitae Corporation (NYSE: NVTA), the fastest growing clinical genetics company, today announced that it will report its fourth quarter and year-end 2018 financial results on Tuesday, February 19, 2019 and will host a conference call and webcast that day at 4:30 p.m. Eastern / 1:30 p.m. Pacific to discuss its financial results and recent developments.
Jan 07, 2019 06:30 am ET
Invitae reports 2018 preliminary financial results, delivering more than 100% volume and revenue growth in 2018; projects sustained growth in expanding markets through 2019 and beyond
SAN FRANCISCO, Jan. 7, 2019 /PRNewswire/ -- Invitae Corporation (NYSE: NVTA), the fastest growing clinical genetics company, announced preliminary unaudited full-year 2018 results showing triple-digit growth driven by strong commercial execution, test menu expansion and the accelerating use of genetics in healthcare.
Dec 20, 2018 03:31 pm ET
Invitae to Present at the 37th Annual J.P. Morgan Healthcare Conference
SAN FRANCISCO, Dec. 20, 2018 /PRNewswire/ -- Invitae Corporation (NYSE: NVTA), one of the fastest growing genetics companies, today announced that Sean George, co-founder and chief executive officer of Invitae, will present at the 37th Annual J.P. Morgan Healthcare Conference on Wednesday, January 9, 2019 at 8:30 a.m. Pacific at the Westin St. Francis Hotel in San Francisco.
Dec 10, 2018 06:30 am ET
New Study Published in Journal of Clinical Oncology Supports Universal Genetic Testing for all Breast Cancer Patients
SAN FRANCISCO, Dec. 10, 2018 /PRNewswire/ -- Current guidelines for genetic testing of breast cancer patients miss as many patients with pathogenic variants (or genetic mutations) as they find, according to a new study published in the Journal of Clinical Oncology by researchers from the TME Breast Care Network, a network of more than 300 leading breast cancer physicians and Invitae (NYSE: NVTA), one of the fastest growing genetics companies. The findings support broadening and simplifying current guidelines to ensure all breast cancer patients have access to genetic information to guide the
Dec 04, 2018 08:15 am ET
Detailed Research: Economic Perspectives on United Technologies, Walmart, Invitae, Emergent Biosolutions, U.S. Physical Therapy, and Amdocs — What Drives Growth in Today's Competitive Landscape
In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of United Technologies Corporation (NYSE:UTX), Walmart Inc. (NYSE:WMT),...
Nov 14, 2018 06:30 am ET
Invitae Highlighting New Research, Honoring Excellence in Genetic Counseling at National Society of Genetic Counselors (NSGC) 37th Annual Conference
ATLANTA, Nov. 14, 2018 /PRNewswire/ -- Researchers from Invitae Corporation (NYSE: NVTA), one of the fastest growing genetics companies, are presenting research at the National Society of Genetic Counselors (NSGC) 37th Annual Conference in Atlanta that further underscores the frequency of medically actionable genetic variants and their utility in clinical care. In addition to its research presentations, the company is supporting the Code Talker award, which recognizes excellence in the field of genetic counseling.
Nov 07, 2018 03:05 pm ET
Invitae Reports 106% Annual Revenue Growth Driven by 95% Annual Growth in Volume in Third Quarter 2018
SAN FRANCISCO, Nov. 7, 2018 /PRNewswire/ -- Invitae Corporation (NYSE: NVTA), one of the fastest growing genetics companies, today announced financial and operating results for the third quarter ended September 30, 2018. Based on progress in the quarter, Invitae is raising its volume guidance from more than 275,000 samples to more than 285,000 samples and raising its revenue guidance from between $135 and $140 million to between $140 and $145 million in 2018.
Oct 29, 2018 07:30 am ET
Invitae expands work with Alnylam Pharmaceuticals to provide access to genetic testing for primary hyperoxaluria
SAN FRANCISCO, Oct. 29, 2018 /PRNewswire/ -- Invitae Corporation (NYSE: NVTA), one of the fastest growing genetics companies, announced today it has expanded its partnership with Alnylam Pharmaceuticals, the leading RNAi therapeutics company, to provide genetic testing at no cost to patients through the Alnylam Act® program for individuals who may carry gene mutations associated with primary hyperoxaluria, an ultra-rare genetic disorder affecting the kidneys that most often presents in childhood.
Oct 25, 2018 08:30 am ET
Report: Exploring Fundamental Drivers Behind Invitae, Aerie Pharmaceuticals, Gevo, Global Medical REIT, Cyclacel Pharmaceuticals, and Toll Brothers — New Horizons, Emerging Trends, and Upcoming Develo
In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of Invitae Corporation (NYSE:NVTA), Aerie Pharmaceuticals, Inc....
Oct 24, 2018 07:30 am ET
Invitae to announce third quarter 2018 financial results on November 7, 2018
SAN FRANCISCO, Oct. 24, 2018 /PRNewswire/ -- Invitae Corporation (NYSE: NVTA), one of the fastest growing genetics companies, today announced that it will report its third quarter 2018 financial results on Wednesday, November 7, 2018 and will host a conference call and webinar that day at 4:30 p.m. Eastern / 1:30 p.m. Pacific to discuss its financial results and recent highlights.
Oct 17, 2018 07:30 am ET
Research shows high positive rate for risk of hereditary disease in study of proactive genetic health screening for healthy people
SAN DIEGO, Oct. 17, 2018 /PRNewswire/ -- Researchers from Invitae Corporation (NYSE: NVTA), one of the fastest growing genetics companies, will present findings showing proactive genetic testing identifies medically significant findings for 16.5 percent of healthy individuals. The data add to a growing body of evidence showing expanding clinical genetic testing to people without identified risks could be beneficial.
Sep 18, 2018 07:30 am ET
Invitae to Present at the Ladenburg Thalmann 2018 Healthcare Conference
SAN FRANCISCO, Sept. 18, 2018 /PRNewswire/ -- Invitae Corporation (NYSE: NVTA), one of the fastest growing genetics companies, today announced that Sean George, co-founder and chief executive officer of Invitae, will present at the Ladenburg Thalmann 2018 Healthcare Conference on Tuesday, October 2, 2018 at 9:00 a.m. Eastern / 6:00 a.m. Pacific in New York City.
Sep 11, 2018 07:30 am ET
Invitae Appoints Chitra Nayak to its Board of Directors
SAN FRANCISCO, Sept. 11, 2018 /PRNewswire/ -- Invitae Corporation (NYSE: NVTA), one of the fastest growing genetics companies, announced the appointment of Chitra Nayak to its Board of Directors, effective September 10, 2018.
Sep 05, 2018 07:40 am ET
Factors of Influence in 2018, Key Indicators and Opportunity within Destination XL Group, Invitae, Federated National Holding, Bridge, QCR, and Kelly Services — New Research Emphasizes Economic Growth
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Destination XL Group, Inc. (NASDAQ:DXLG), Invitae Corporation (NYSE:NVTA),...
Aug 16, 2018 08:15 am ET
Investor Expectations to Drive Momentum within Global Medical REIT, Cyclacel Pharmaceuticals, Super Micro Computer, Kelly Services, Invitae, and ScanSource — Discovering Underlying Factors of Influenc
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Global Medical REIT Inc. (NYSE:GMRE), Cyclacel Pharmaceuticals, Inc....
Aug 07, 2018 04:05 pm ET
Invitae Reports More than 160% Annual Revenue Growth Driven by Nearly 140% Annual Growth in Volume in Second Quarter 2018
SAN FRANCISCO, Aug. 7, 2018 /PRNewswire/ -- Invitae Corporation (NYSE: NVTA), one of the fastest growing genetics companies, today announced financial and operating results for the second quarter ended June 30, 2018. Based on progress in the quarter, Invitae is raising its revenue guidance from more than $130 million to between $135 and $140 million in 2018.
Jul 24, 2018 07:30 am ET
Invitae to announce second quarter 2018 Financial Results on August 7, 2018
SAN FRANCISCO, July 24, 2018 /PRNewswire/ -- Invitae Corporation (NYSE: NVTA), one of the fastest growing genetics companies, today announced that it will report its second quarter 2018 financial results on Tuesday, August 7, 2018 and will host a conference call and webinar that day at 4:30 p.m. Eastern / 1:30 p.m. Pacific to discuss its financial results and recent highlights.
Jun 25, 2018 07:30 am ET
Invitae Expands Reproductive Health Offering with Launch of Comprehensive Genetic Carrier Screening
SAN FRANCISCO, June 25, 2018 /PRNewswire/ -- Invitae Corporation (NYSE: NVTA), one of the fastest growing genetics companies, today announced the launch of the Invitae Carrier Screen, a comprehensive test designed to provide affordable, accessible information on genetic changes that pose a risk for parents of having a child with an inherited genetic disorder. Each year 7.8 million children worldwide are born with health problems caused at least in part by genetics1.
Jun 13, 2018 07:30 am ET
Invitae Study of 143,000 Patients Shows Importance of Routinely Including Deletion and Duplication Detection with Sequencing in Genetic Testing
SAN FRANCISCO, June 13, 2018 /PRNewswire/ -- Researchers from Invitae, one of the fastest growing genetics companies, today published findings from the largest analysis to date of genetic testing to identify deletions and duplications involving single genes using next-generation sequencing (NGS) techniques. The study found that these changes, also called exonic copy number variants (CNVs), are present in a substantial number of patients and suggested that CNV testing should be universally used in clinical genetic testing. With few exceptions, these types of exonic CNVs are not typically dete
May 30, 2018 07:30 am ET
Invitae to Present at the William Blair 2018 Growth Stock Conference
SAN FRANCISCO, May 30, 2018 /PRNewswire/ -- Invitae Corporation (NYSE: NVTA), one of the fastest growing genetics companies, today announced that Sean George, co-founder and chief executive officer of Invitae, will present at the William Blair 2018 Growth Stock Conference on Tuesday, June 12, 2018 at 4:10 p.m. Central / 5:10 p.m. Eastern / 2:10 p.m. Pacific in Chicago.
May 09, 2018 04:05 pm ET
Invitae Reports 169% Revenue Growth Driven by 150% Growth in Volume in First Quarter 2018
SAN FRANCISCO, May 9, 2018 /PRNewswire/ -- Invitae Corporation (NYSE: NVTA), one of the fastest growing genetics companies, today announced financial and operating results for the first quarter ended March 31, 2018. Based on the growing momentum in test volume and substantial revenue growth, the company is increasing its volume guidance from accessioning 250,000 samples to accessioning more than 275,000 samples in 2018. Additionally, the company is raising its revenue guidance from at least $120 million to more than $130 million in 2018.
May 07, 2018 07:30 am ET
Sarepta and Invitae Expand Partnership to Advance Clinical Research in Duchenne Muscular Dystrophy
SAN FRANCISCO, May 7, 2018 /PRNewswire/ -- Invitae Corporation (NYSE: NVTA), one of the fastest growing genetics companies, today announced the expansion of its partnership with Sarepta Therapeutics, Inc. (NASDAQ: SRPT) to assist clinicians in identifying patients with Duchenne muscular dystrophy (DMD).
May 04, 2018 07:55 am ET
Market Trends Toward New Normal in LRAD, Xencor, QuinStreet, Old Second, WesBanco, and Invitae — Emerging Consolidated Expectations, Analyst Ratings
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of LRAD Corporation (NASDAQ:LRAD), Xencor, Inc. (NASDAQ:XNCR), QuinStreet,...
May 03, 2018 07:30 am ET
Invitae to participate in two upcoming investor conferences, the Bank of America Merrill Lynch 2018 Heath Care Conference and the UBS Global Healthcare Conference
SAN FRANCISCO, May 3, 2018 /PRNewswire/ -- Invitae Corporation (NYSE: NVTA), one of the fastest growing genetics companies, today announced that Sean George, co-founder and chief executive officer of Invitae, will participate in two upcoming investor conferences:
Apr 27, 2018 07:30 am ET
Invitae Announces New Program to Offer Genetic Testing to Aid Diagnosis of Spinal Muscular Atrophy (SMA)
SAN FRANCISCO, April 27, 2018 /PRNewswire/ -- Invitae Corporation (NYSE: NVTA), one of the fastest growing genetics companies, today announced that it is launching a new program with Biogen, a leading biotechnology company, to offer genetic testing at no charge to patients suspected of having or clinically diagnosed with spinal muscular atrophy (SMA), a rare, progressive, genetic, neuromuscular disease. The program, SMA Identified, is the latest addition to Invitae's network of partnerships that connect patients and clinicians to treatment and research.
Apr 25, 2018 07:30 am ET
Invitae to Announce First Quarter 2018 Financial Results on May 9, 2018
SAN FRANCISCO, April 25, 2018 /PRNewswire/ -- Invitae Corporation (NYSE: NVTA), one of the fastest growing genetics companies, today announced that it will report its first quarter 2018 financial results on Wednesday, May 9, 2018 and will host a conference call and webinar that day at 4:30 p.m. Eastern / 1:30 p.m. Pacific to discuss its financial results and recent highlights.
Apr 10, 2018 07:30 am ET
Invitae research highlights utility of proactive genetic screening, importance of assessing secondary findings in genetic testing
CHARLOTTE, N.C., April 10, 2018 /PRNewswire/ -- Researchers from Invitae Corporation (NYSE: NVTA), one of the fastest growing genetic information companies, will present findings showing proactive genetic health screening reveals medically significant findings for a substantial portion of patients, and looking for secondary findings during genetic testing provides a substantial yield of actionable risk factors for disease. The studies are among the company's data being presented this week at the American College of Medical Genetics (ACMG) annual meeting in Charlotte, NC.
Mar 28, 2018 06:00 am ET
Invitae Announces Pricing of Public Offering of Common Stock
SAN FRANCISCO, March 28, 2018 /PRNewswire/ -- Invitae Corporation (NYSE: NVTA) today announced the pricing on March 27, 2018 of an underwritten public offering of 11,111,111 shares of its common stock at a price to the public of $4.50 per share. All of the shares are being sold by Invitae. The gross proceeds to Invitae from the offering, before deducting the underwriting discounts and commissions and other offering expenses, are expected to be approximately $50.0 million. The offering is expected to close on or about April 2, 2018, subject to customary closing conditions. In addition, Invita
Disclaimer :: Use of this site is subject to, and your continued use
constitutes your express agreement to be bound by, our Legal and Terms of Use. Any commercial use of this site is
strictly prohibited. Insidertracking.com is operated by INK Research Corp (INK). INK provides general information.
INK has made all reasonable efforts to ensure that all information provided is accurate at the time of inclusion;
however, there may be errors. INK makes no guarantee of accuracy or completeness. All information and opinion
expressed herein is subject to change without notice. Insider information is based on filings made either on EDGAR®
or on the System for Electronic Disclosure for Insiders (SEDI®). Data is provided “as is” and by using this site
you acknowledge that the information which comprises the data is filed by or on behalf of the SEDI filers or other
parties legally required or permitted to do so. Filings may at any time contain errors and by using this site you
acknowledge this fact. INK is not an investment advisory service, a financial planner, an investment advisor nor a
securities advisor. INK does not purport to tell people, or suggest to people, what they should buy or sell for
themselves. Opinions and recommendations contained herein should not be construed as investment advice. Do not
assume that any recommendations, insights, charts, theories, or philosophies will ensure profitable investment.
Users should always consult with and obtain advice from their professional licensed financial advisor, including
their tax advisor, to determine the suitability of any investment. INK recommends that anyone making an investment
or trading securities do so with caution. Users should perform full due diligence and investigate any security
fully before making an investment or before the execution of a security trade based upon information learned
through INK. Investors should obtain annual reports and other company information to complete their own due
diligence in any investment. Neither INK nor anyone affiliated with INK is responsible for any investment decision
made. INK employees may have an ownership or investment interest in any stock mentioned in this service or on this
website. On this site, there may be third party content, content from authors or links to third-party sites or
pages, the contents of which are not verified, maintained, controlled or supervised by INK. INK is not responsible
for and assumes no liability for the accuracy, completeness or timeliness of any third party content or authored
content provided herein or the information or contents of any linked sites or pages. The inclusion of any authored
content or link by us does not imply that INK recommends, approves or endorses the authored content or linked site
or pages. INK Edge® and INK Research® are registered trade-marks owned by INK Research Corp. SEDI®
is a registered trade-mark owned by the Alberta Securities Commission. Copyright © 2024 INK Research Corp. All rights reserved.
Please make the indicated changes including the new text: US quotes snapshot data provided by IEX. Additional price data and company information powered by Twelve Data.
Please make the indicated changes including the new text: US quotes snapshot data provided by IEX. Additional price data and company information powered by Twelve Data.